| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -10,143,939 | -7,171,529 |
| Depreciation and amortization | 16,286 | 10,857 |
| Stockbased compensation | 369,117 | 255,363 |
| Foreign currency loss (gain) | -86,618 | -80,927 |
| Prepaid expenses and other current and noncurrent assets | -517,745 | -347,749 |
| Accounts payable | -715,625 | -161,605 |
| Accrued expenses | -63,349 | -123,679 |
| Net cash used in operating activities | -9,933,147 | -6,761,917 |
| Proceeds from issuance of common stock | 834,397 | 459,019 |
| Common stock issuance costs | 35,729 | 18,291 |
| Net cash provided by financing activities | 798,668 | 440,728 |
| Change in cash, cash equivalents and restricted cash | -9,134,479 | -6,321,189 |
| Effect of exchange rate changes on cash | 3,406 | - |
| Cash and cash equivalents at beginning of period | 22,890,055 | - |
| Cash and cash equivalents at end of period | 13,758,982 | - |
Aprea Therapeutics, Inc. (APRE)
Aprea Therapeutics, Inc. (APRE)